Shurduk, Artem

Email Address
ORCID
Disciplines
Research Projects
Organizational Units
Position
Introduction
Research Interests

Search Results

Now showing 1 - 1 of 1
  • Publication
    Adjunctive Therapy of Periodontal Disease with Minocycline Microspheres in Dental School Settings: A Retrospective Chart Review.
    (2020-11-11) Shurduk, Artem
    Background: The chronic periodontitis is a highly prevalent disease that affects over 60% of people older than 65 and 10-15% is a prevalence of severe form. The Scaling and root planing procedure (SRP) is a gold standard of periodontal treatment which effectiveness was proven through numerous longitudinal studies. The nature of this treatment is to mechanically disrupt bacterial biofilm, remove subgingival calculus, and infected cement layer from the affected root surface to create favorable conditions for repair and regeneration. Different adjunctive therapies are utilized to further improve outcomes with a range of 0.2-0.6 mm of CAL improvement (compared to SRP alone). Local delivery minocycline microspheres were extensively investigated and showed a statistically significant difference in a mean reduction of PD compared to SRP alone. The objective of the present study is to assess the efficacy of adjunctive therapy with minocycline microspheres in dental school settings measured in mean probing depth reduction. Material and methods. 1660 patients were included in the present study. 540 patients for the test group and 1130 patients for the control group were identified through an automated search. Clinical and demographic data were extracted and analyzed. Mean PD reduction and BOP reduction was calculated for test and control groups as well as for subgroups based on the criteria of health history (smoking, diabetes, cardiovascular disease, arthritis), disease severity (initial probing depth, ADA case type). Percentages of sites reached the threshold of PD reduction of 1 and 2 mm were calculated for subgroups stratified by the initial PD and compared in test and control groups. Results: For the Arestin group, mean short-term PD reduction was 1.14 mm, and long-term PD reduction was 1.18 mm. BOP reduction for the test group was 10.6% in the short-term follow-up and - 4.24% for a long-term period. Results: Control group showed a PD reduction of 1.2 mm for the short-term period and 1.5 mm for the long-term. BOP reduction was 12.95% for the short-term period and 8.19% for the long-term follow up, which was significantly higher than in the test group. Although the long-term PD reduction was significantly greater in the Control group, the difference in short-term PD reduction was not significant. There were no statistically significant differences in the percentage of sites reached PD ≤ 4 mm between test and control groups.